Pemetrexed, paclitaxel regimens equally effective in NSCLC
PointBreak trial results suggest that pemetrexed- and paclitaxel-based chemotherapy offer comparable survival outcomes and tolerability for patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) but with differing toxicity profiles. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 10, 2013 Category: Cancer & Oncology Source Type: news
Low sodium levels linked to poor targeted therapy outcomes in RCC
Low serum sodium levels in patients receiving targeted therapy for metastatic renal cell carcinoma (mRCC) may signal a poor outcome, study findings indicate. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 9, 2013 Category: Cancer & Oncology Source Type: news
Early tumor shrinkage predicts targeted therapy efficacy in RCC
Early tumor shrinkage in patients with metastatic renal cell carcinoma following vascular endothelial growth factor-targeted therapy may herald good long-term survival, research shows. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 9, 2013 Category: Cancer & Oncology Source Type: news
Novel multi-kinase inhibitor shows early promise in NSCLC
Researchers have reported promising early data on an investigational drug that targets two tyrosine kinase receptors that drive invasive growth and drug resistance in non-small-cell lung cancer. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 9, 2013 Category: Cancer & Oncology Source Type: news
Training advised to plug lung cancer care gaps
Guideline-consistent care for patients with suspected lung cancer with mediastinal lymphadenopathy without distant metastases varies by region and physician characteristics, say researchers. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 5, 2013 Category: Cancer & Oncology Source Type: news
Lung cancer is costliest cancer in European Union
The total cost of cancer care across the European Union was an estimated € 126 billion in 2009, with lung cancer having the highest cost, at 15% of the total. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 4, 2013 Category: Cancer & Oncology Source Type: news
Investigational c-Met inhibitor shows early promise in NSCLC
A first-in-class drug that inhibits c-Met, a receptor tyrosine kinase, has demonstrated good tolerability when combined with erlotinib in the treatment of Japanese patients with advanced/metastatic non-small-cell lung cancer. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 3, 2013 Category: Cancer & Oncology Source Type: news
Clinicians ‘nihilistic’ toward lung cancer patients
Clinicians tend to view their lung cancer patients more negatively than patients with other solid tumors, study findings indicate. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 3, 2013 Category: Cancer & Oncology Source Type: news
Four-drug regimen shows first-line efficacy in advanced NSCLC
A four-drug combination of cetuximab, bevacizumab, carboplatin, and paclitaxel is effective and has acceptable safety as a first-line treatment for advanced non-small-cell lung cancer, US researchers report. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 2, 2013 Category: Cancer & Oncology Source Type: news
Endobronchial ultrasound has edge for lung cancer staging
Endobronchial ultrasound-guided transbronchial needle aspiration is a better primary procedure than endoscopic ultrasound-guided fine needle aspiration for staging non-small-cell lung cancer, study results suggest. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - December 1, 2013 Category: Cancer & Oncology Source Type: news
Smoking reduces nasopharyngeal cancer survival
Both current and former smoking have a significant impact on the prognosis of patients with nasopharyngeal carcinoma, Chinese researchers caution. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - November 27, 2013 Category: Cancer & Oncology Source Type: news
Medical–surgical integration ‘boosts neoadjuvant chemotherapy use for bladder cancer’
Research from the USA indicates that a multidisciplinary approach and coordination between medical and surgical oncology services can help optimize the use of neoadjuvant chemotherapy for bladder cancer. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - November 18, 2013 Category: Cancer & Oncology Source Type: news
Pneumococcal pneumonia linked to lung cancer risk
Pneumococcal pneumonia is significantly associated with risk for lung cancer, show findings from a national study in Taiwan. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - November 13, 2013 Category: Cancer & Oncology Source Type: news
Toxicity limits benefits of bevacizumab–erlotinib NSCLC maintenance therapy
Two targeted anticancer drugs used together after first-line chemotherapy for advanced stage non-small-cell lung cancer improve progression-free survival, the results of a large, prospective study show. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - November 4, 2013 Category: Cancer & Oncology Source Type: news
Current drugs may harbor small-cell lung cancer promise
Scientists have identified several existing non-oncology drug classes that may have potential as a treatment for small-cell lung cancer, especially for patients with chemoresistant and metastatic disease. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - October 31, 2013 Category: Cancer & Oncology Source Type: news
